Stay updated on APG-115 + Pembrolizumab in Metastatic Melanomas Clinical Trial
Sign up to get notified when there's something new on the APG-115 + Pembrolizumab in Metastatic Melanomas Clinical Trial page.

Latest updates to the APG-115 + Pembrolizumab in Metastatic Melanomas Clinical Trial page
- Check6 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content.SummaryDifference0.2%
- Check13 days agoChange DetectedThe web page has been updated to include new facility names and locations, specifically adding Washington D.C. and St. Louis, along with relevant medical terms related to uveal melanoma and other eye diseases. The revision number has also been updated to v3.0.0.SummaryDifference5%
- Check21 days agoNo Change Detected
- Check28 days agoChange DetectedThe web page has been updated from version 2.16.11 to version 2.16.12.SummaryDifference0.1%
- Check35 days agoChange DetectedThe webpage has undergone significant changes, including the removal of multiple study contact details and the addition of new dates for 2025. Notably, the revision number has been updated to v2.16.11.SummaryDifference9%
- Check42 days agoChange DetectedThe web page has been updated to version 2.16.10, and a previous service alert regarding planned maintenance has been removed.SummaryDifference1.0%
- Check49 days agoChange DetectedThe page has been updated to reflect a new version, changing from Revision v2.16.6 to v2.16.8, indicating a potential improvement or update in the content or functionality.SummaryDifference0.2%
Stay in the know with updates to APG-115 + Pembrolizumab in Metastatic Melanomas Clinical Trial
Enter your email address, and we'll notify you when there's something new on the APG-115 + Pembrolizumab in Metastatic Melanomas Clinical Trial page.